Ge
Non verificato

GenSight Biologics S.A.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOtticaSalute
08/10/2026
Mercato del lavoro
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Ottica
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
1.00
07/10/2026
Scienza
Biotecnologia
Farmaceutica
Ottica
Salute
GenSight Biologics Reports Cash Position as of September 30, 2026
1.00
29/09/2026
Mercato azionario
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Ottica
GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
1.00
08/07/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates
1.00
18/05/2026
Salute
Medicina - Varie
Farmaceutica
Ottica
Biotecnologia
GenSight Biologics to Hold its Combined General Meeting on May 19, 2026
1.00
11/05/2026
Industria
Libri/Editoria
Biotecnologia
Comunicazione
Medicina - Varie
Salute
Farmaceutica
Ottica
GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments
1.00
28/04/2026
Web e Social Network
Finanza
Salute
Biotecnologia
Farmaceutica
Ottica
GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026
1.00
18/02/2026
Salute
Biotecnologia
Sanità
Medicina - Varie
Ottica
Mercato del lavoro
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments
1.00
10/02/2026
Biotecnologia
Farmaceutica
Ottica
Sanità
Salute
Medicina - Varie
Mercato del lavoro
Industria
The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study
1.00
28/01/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0